Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EBIT: 2015-2024

Historic EBIT for Insight Molecular Diagnostics (IMDX) over the last 10 years, with Dec 2024 value amounting to -$61.0 million.

  • Insight Molecular Diagnostics' EBIT rose 18.25% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 40.66%. This contributed to the annual value of -$61.0 million for FY2024, which is 142.84% down from last year.
  • Latest data reveals that Insight Molecular Diagnostics reported EBIT of -$61.0 million as of FY2024, which was down 142.84% from -$25.1 million recorded in FY2023.
  • In the past 5 years, Insight Molecular Diagnostics' EBIT registered a high of -$18.0 million during FY2022, and its lowest value of -$61.0 million during FY2024.
  • For the 3-year period, Insight Molecular Diagnostics' EBIT averaged around -$34.7 million, with its median value being -$25.1 million (2023).
  • As far as peak fluctuations go, Insight Molecular Diagnostics' EBIT surged by 66.50% in 2022, and later slumped by 142.84% in 2024.
  • Insight Molecular Diagnostics' EBIT (Yearly) stood at -$29.7 million in 2020, then plummeted by 80.83% to -$53.7 million in 2021, then skyrocketed by 66.50% to -$18.0 million in 2022, then crashed by 39.67% to -$25.1 million in 2023, then tumbled by 142.84% to -$61.0 million in 2024.